Good
Mostly Aligned
Patient Risk:
Low
Summary
Most claims about administration and indications are directionally consistent with the provided label excerpts for PERSERIS, but the supplied prescribing information text does not include details needed to fully verify dosing frequency/administration device, and it does not include indication text for schizophrenia or bipolar I disorder.
Category Scores
Accurate Statements
Perseris is administered as a subcutaneous injection.
Supported by provided dosage form description: 'extended-release injectable suspension for subcutaneous use (90 mg or 120 mg)'.
Perseris (risperidone) subcutaneous injection for extended-release is administered once a month.
Not verifiable from the provided label excerpts. No timing/frequency statement is present in the supplied text.
Perseris is administered as a pre-filled syringe.
Not verifiable from the provided label excerpts. No syringe/device description is present in the supplied text.
Perseris is indicated for the treatment of schizophrenia in adults.
Not verifiable from the provided label excerpts. Indication text is not included in the supplied text.
Perseris is indicated for the treatment of bipolar I disorder in adults.
Not verifiable from the provided label excerpts. Indication text is not included in the supplied text.
Elderly patients with dementia-related psychosis treated with PERSERIS have an increased risk of death, and PERSERIS is not approved for this indication.
Supported by Section 5.1: 'Elderly patients with dementia-related psychosis... at an increased risk of death' and 'PERSERIS is not approved for the treatment of patients with dementia-related psychosis'; and Section 8.5 reiteration.
Unsupported Statements
Perseris (risperidone) subcutaneous injection for extended-release is administered once a month.
The supplied prescribing information excerpts do not contain any dosing interval/frequency statement.
Perseris is administered as a pre-filled syringe.
The supplied prescribing information excerpts do not contain any statement describing the device as a pre-filled syringe.
Perseris is indicated for the treatment of schizophrenia in adults.
The supplied prescribing information excerpts do not include the Indications section.
Perseris is indicated for the treatment of bipolar I disorder in adults.
The supplied prescribing information excerpts do not include the Indications section.
Contradictions
Important Omissions
For the administration/dosing claims (e.g., once-monthly schedule) and indication claims (schizophrenia and bipolar I disorder), the label excerpts provided do not include the relevant sections needed to confirm those details.
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Low
The only fully label-verifiable safety-related claim (increased mortality in elderly patients with dementia-related psychosis and lack of approval for that indication) is supported by the provided label text.
Regulatory Assessment
| On Label |
Yes |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Medium |
Recommendation
Mostly Aligned
Primary Issue
Several claims (once-monthly frequency, pre-filled syringe device, and schizophrenia/bipolar I indications) are not supported by the prescribing information excerpts provided in the prompt.
Suggested Improvement
Limit statements to label-supported information from the provided excerpts (e.g., subcutaneous route and the dementia-related psychosis mortality/non-approval warning) or provide the missing Indications and Dosage/Administration label sections to verify frequency and device details.